Drugmakers Sage Therapeutics and Biogen are still ironing out how much their newly approved postpartum depression medication, zuranolone, will cost once it’s made commercially available in the United States this year.
Zuranolone, sold under the brand name Zurzuvae, is expected to launch in the fourth quarter of 2023, and the companies’ goal is for the medication to be…